APA (7th ed.) Citation

DY, R., HX, W., SX, L., WW, H., XJ, L., ZX, N., . . . RH, X. (2025). The antibody-drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: A phase 1 trial. Nature medicine, 31(9), 3037. https://doi.org/10.1038/s41591-025-03781-w

Chicago Style (17th ed.) Citation

DY, Ruan, et al. "The Antibody-drug Conjugate SHR-A1904 for Targeting CLDN18.2 in Advanced Gastric or Gastroesophageal Junction Cancer: A Phase 1 Trial." Nature Medicine 31, no. 9 (2025): 3037. https://doi.org/10.1038/s41591-025-03781-w.

MLA (9th ed.) Citation

DY, Ruan, et al. "The Antibody-drug Conjugate SHR-A1904 for Targeting CLDN18.2 in Advanced Gastric or Gastroesophageal Junction Cancer: A Phase 1 Trial." Nature Medicine, vol. 31, no. 9, 2025, p. 3037, https://doi.org/10.1038/s41591-025-03781-w.